Explainer
Multiple sclerosis explained: types, causes and treatment
Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, damaging the myelin that insulates nerve fibres. WHO estimates over 1.8 million people have it.[1][2] It usually starts between ages 20 and 40 and is two to three times more common in women.[3] There is no cure, but disease-modifying therapies can reduce relapses and slow progression, and most people with MS have a normal life expectancy.[4][5][6]
This page explains multiple sclerosis and its treatments. It is not medical advice. If you have symptoms or questions about MS treatment, talk to a doctor or neurologist. This page gives no dosing information.
Multiple sclerosis (MS) happens when the immune system attacks the brain and spinal cord, damaging myelin, the protective coating around nerve fibres.[1] WHO estimates that over 1.8 million people worldwide have MS.[2]
What MS does
The “sclerosis” in the name refers to patches of scar-like tissue, called plaques or lesions, that form where myelin has been attacked and that show up on MRI scans.[7] Common symptoms include vision problems, fatigue, trouble walking and keeping balance, and numbness or weakness in the arms and legs. Many people find symptoms get worse with heat, fever or common infections.[8]
The NHS warns that sudden weakness or numbness in one arm, sudden loss or blurring of vision, or sudden problems with balance and co-ordination could be signs of a stroke and need emergency care.[9]
Types of MS
In the most common type, relapsing-remitting MS, symptoms flare up in attacks and then partly or fully go away. Over time this can turn into secondary-progressive MS, where symptoms slowly worsen. A less common type, primary-progressive MS, gets steadily worse from the start without clear attacks.[10]
WHO and NINDS describe relapsing-remitting MS (RRMS) as the most common course, with relapses followed by remissions; RRMS can evolve into secondary-progressive MS (SPMS). Primary-progressive MS (PPMS) is less common and worsens from onset without acute attacks.[10]
Who gets MS
Symptoms usually begin between ages 20 and 40, and MS is two to three times more common in women than in men.[3] MS is not an inherited disorder, but having a parent or sibling with MS raises the risk, and research suggests hundreds of gene variants combine to create vulnerability.[11]
The virus most consistently linked to MS is Epstein-Barr virus (EBV), which causes infectious mononucleosis. The roughly 5% of people never infected with it have a lower risk.[12] Research also links more sun exposure and higher vitamin D levels to lower risk, and smoking to higher risk and a more aggressive course.[13]
Diagnosis
There is no single test for MS.[14] Doctors combine a neurological exam with MRI scans of the brain and spinal cord to look for the characteristic lesions, and may use a lumbar puncture to examine spinal fluid.[14]
Treatment
There is no cure, but treatments can slow progression and ease symptoms.[4] Corticosteroids are used for relapses; trials show they speed recovery from attacks but do not change the long-term course.[15]
Disease-modifying therapies approved by the FDA regulate or suppress the inflammation behind MS and work best in relapsing forms.[5] They come as infusions, pills and injections.[5] NINDS says ocrelizumab, an infusion that targets B cells, is currently the only FDA-approved disease-modifying therapy for primary-progressive MS.[16] Each drug has its own risks: natalizumab, for example, is very effective but raises the risk of PML, a serious and potentially fatal viral brain infection.[17]
Outlook
MS affects people differently, and NINDS says most people with MS have a normal life expectancy.[6] MS is one of several autoimmune conditions; coeliac disease is another, in which the immune system attacks the small intestine.[18][19] For other neurological conditions, see epilepsy and Parkinson’s disease, which affect around 50 million and over 8.5 million people worldwide respectively, according to WHO.[20][21]
Read next
Coeliac disease explained: symptoms, diagnosis and gluten-free labels
What coeliac (celiac) disease is, who gets it, how it is diagnosed, why the treatment is a lifelong gluten-free diet, and what a US "gluten-free" label means.
Questions readers ask
What causes MS?
The exact cause is unknown. MS is not inherited, but having an affected parent or sibling raises the risk, and hundreds of gene variants seem to contribute. Epstein-Barr virus is the virus most consistently linked to MS, and smoking and low sun exposure or vitamin D are also associated with higher risk.[11][12][13]
What are the first symptoms of MS?
Common symptoms include vision problems, fatigue, trouble walking and balancing, and numbness or weakness in the arms and legs. Symptoms can worsen with heat, fever or infection.[8]
What are the types of MS?
Relapsing-remitting MS, with attacks followed by recovery, is the most common. It can later become secondary-progressive MS. Primary-progressive MS worsens steadily from the start and is less common.[10]
How is MS diagnosed?
There is no single test. Doctors use a neurological exam and MRI scans of the brain and spinal cord to look for lesions, sometimes with a lumbar puncture.[14]
Can MS be cured?
No. Treatments can reduce relapses, slow progression and ease symptoms. Steroids speed recovery from attacks, and disease-modifying therapies work best in relapsing forms.[4][15][5]
Does MS shorten life?
NINDS says most people with MS have a normal life expectancy.[6]
Sources
· 21 claims from 5 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Multiple sclerosis is a condition in which the immune system attacks the brain and spinal cord, damaging myelin, the protective coating around nerve fibres. confirmedas of 2026-11-07
- Multiple sclerosis (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Myelin and the immune system (retrieved 2026-11-07)
- [2]
WHO estimates that over 1.8 million people worldwide have MS. confirmedas of 2026-11-07
- Multiple sclerosis (fact sheet) · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [3]
MS symptoms usually begin between ages 20 and 40, and MS is two to three times more common in women than in men. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · What is multiple sclerosis? (retrieved 2026-11-07)
- Multiple Sclerosis · MedlinePlus (National Library of Medicine) · Primary source · Who is at risk (retrieved 2026-11-07)
- [4]
There is no cure for MS, but treatments can reduce relapses, slow progression and ease symptoms. confirmedas of 2026-11-07
- Multiple sclerosis (MS) · NHS · Primary source · Treatment (retrieved 2026-11-07)
- Multiple sclerosis (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- [5]
FDA-approved disease-modifying therapies for MS regulate or suppress the disease's inflammatory reactions and work best in relapsing forms; they are given as infusions, pills or injections. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Disease-modifying treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Disease-modifying treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Disease-modifying treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Disease-modifying treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Disease-modifying treatments (retrieved 2026-11-07)
- [6]
MS affects people differently, and most people with MS have a normal life expectancy. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · What is multiple sclerosis? (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · What is multiple sclerosis? (retrieved 2026-11-07)
- [7]
The "sclerosis" in the name refers to areas of scar-like tissue, also called plaques or lesions, that are visible on MRI. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Myelin and the immune system (retrieved 2026-11-07)
- [8]
Common symptoms include vision problems, fatigue, trouble walking and balancing, and numbness or weakness in the arms and legs; symptoms can worsen with heat, fever or infection. confirmedas of 2026-11-07
- Multiple sclerosis (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Symptoms of MS (retrieved 2026-11-07)
- [9]
The NHS says sudden weakness or numbness in one arm, loss or blurring of vision, or problems with balance and co-ordination could be signs of a stroke and need emergency care. confirmedas of 2026-11-07
- Multiple sclerosis (MS) · NHS · Primary source · When and where to get medical help (retrieved 2026-11-07)
- Multiple sclerosis (MS) · NHS · Primary source · When and where to get medical help (retrieved 2026-11-07)
- Multiple sclerosis (MS) · NHS · Primary source · When and where to get medical help (retrieved 2026-11-07)
- [10]
Relapsing-remitting MS, with attacks followed by full or partial recovery, is the most common form; it can evolve into secondary-progressive MS, while primary-progressive MS worsens steadily from the start and is less common. confirmedas of 2026-11-07
- Multiple sclerosis (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Types of MS (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Types of MS, primary-progressive (retrieved 2026-11-07)
- [11]
MS is not an inherited disorder, but having an affected parent or sibling raises the risk, and research suggests hundreds of gene variants combine to create vulnerability. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Who is more likely to get multiple sclerosis? (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Who is more likely to get multiple sclerosis? (retrieved 2026-11-07)
- [12]
The virus most consistently linked to MS is Epstein-Barr virus, which causes infectious mononucleosis; the roughly 5% of people never infected have a lower risk. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Who is more likely to get multiple sclerosis? (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Who is more likely to get multiple sclerosis? (retrieved 2026-11-07)
- [13]
Research links more sun exposure and higher vitamin D levels to lower MS risk, and smoking to higher risk and a more aggressive course. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Who is more likely to get multiple sclerosis? (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Who is more likely to get multiple sclerosis? (retrieved 2026-11-07)
- [14]
There is no single test for MS; doctors use neurological exams, MRI of the brain and spinal cord to look for lesions, and sometimes a lumbar puncture or evoked potential tests. confirmedas of 2026-11-07
- Multiple sclerosis (MS) · NHS · Primary source · Tests for multiple sclerosis (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosing MS (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosing MS (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosing MS (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Diagnosing MS (retrieved 2026-11-07)
- [15]
Corticosteroids are used for relapses; trials show they speed recovery from attacks but do not change the long-term outcome. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Treating MS (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Treating MS (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Treating MS (retrieved 2026-11-07)
- [16]
NINDS says ocrelizumab, a B-cell-targeting infusion, is currently the only FDA-approved disease-modifying therapy for primary-progressive MS. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Infusion treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Infusion treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Infusion treatments (retrieved 2026-11-07)
- [17]
Natalizumab is very effective but carries an increased risk of PML, a serious and potentially fatal viral brain infection. confirmedas of 2026-11-07
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Infusion treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Infusion treatments (retrieved 2026-11-07)
- Multiple Sclerosis (MS) · National Institute of Neurological Disorders and Stroke (NIH) · Primary source · Infusion treatments (retrieved 2026-11-07)
- [18]
Coeliac disease is an autoimmune condition, in which the immune system mistakenly attacks the body's own tissue. confirmedas of 2026-11-07
- Coeliac disease · NHS · Primary source · What causes coeliac disease? (retrieved 2026-11-07)
- Celiac disease (MedlinePlus Genetics) · MedlinePlus (National Library of Medicine) · Primary source · Description (retrieved 2026-11-07)
- [19]
Coeliac (celiac) disease is a chronic digestive and immune disorder in which eating gluten triggers damage to the small intestine. confirmedas of 2026-11-07
- Celiac Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Overview (retrieved 2026-11-07)
- [20]
WHO describes epilepsy as a chronic noncommunicable brain disease affecting around 50 million people worldwide, characterised by recurrent seizures. confirmedas of 2026-11-07
- Epilepsy (fact sheet) · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- [21]
WHO says the global prevalence of Parkinson's doubled over 25 years, with over 8.5 million people living with it in 2019. confirmedas of 2019-12-31
- Parkinson disease (fact sheet) · World Health Organization · Primary source · Assessment and disease burden (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: May 7, 2027.
Cite this page
"Multiple sclerosis explained: types, causes and treatment." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/multiple-sclerosis-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.